Pure Global
NCT06290869

Tobacco Education and Lung Health Study (TEAL)

Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at MedStar Health: A Randomized Trial (Tobacco Education and Lung Health Study)
Georgetown University·Phase 3·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Smoking Cessation
Drug/Device/Intervention
Phone-based Tobacco Treatment, Nicotine Replacement, and Stepped Care Intervention
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Georgetown University
Location
Washington, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Feb 22, 2024
End date
Apr 01, 2026
Enrollment
1188 participants
Primary outcome

Biochemically verified smoking abstinence- MHS vs. QL-E arms,Biochemically verified smoking abstinence--continued MHS arm vs Stepped Care

Summary

Primary Objective To compare two smoking cessation interventions among individuals undergoing
 lung cancer screening. Primary outcomes are: 3-month self-reported abstinence from cigarettes
 and 6-month self-reported and bioverified abstinence from cigarettes.
 
 Secondary Objectives 1) To evaluate reach and engagement overall and by subgroup (e.g., race
 and ethnicity, underinsured, readiness to quit). 2) To conduct an economic analysis to
 evaluate intervention costs from the health system perspective.

ICD-10 classifications
Mental and behavioural disorders due to use of tobacco withdrawal stateTobacco useExposure to tobacco smokeToxic effect: Tobacco and nicotineMental and behavioural disorders due to use of tobacco
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06290869
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06290869 through Pure Global AI's free database. This Phase 3 trial is sponsored by Georgetown University and is currently Recruiting. The study focuses on Smoking Cessation. Target enrollment is 1188 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.